Incyte Corporation vs Shell PLC — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Shell PLC trades at $86.69 (market cap $235.24B). The key difference: Shell PLC is far larger — about 10.2× Incyte Corporation's market cap, and Shell PLC pays a 3.63% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | SHEL | |
|---|---|---|
Market Cap | $23.11B | $235.24B |
Sector | Health | Energy |
52-Week High | $118.52 | $94.15 |
52-Week Low | $67.38 | $70.31 |
Enterprise Value | $19.13B | $287.77B |
Dividend Yield | — | 3.63% |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →